

## Instructions for Authors 2019

**General Policy.** IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis. The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**Open Access Policy.** IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 600.00 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

**Copyright.** Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear **at the end** of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

**Tables.** All tables should appear **at the end** of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dagleish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index2.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html). Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

**Nomenclature and Abbreviations.** Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC -IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

**Ethical Policies and Standards.** IN VIVO agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### **Specific information and additional instructions for Authors**

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.

3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
5. Authors should pay attention to the following points when writing an article for IN VIVO:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
8. Articles submitted to IN VIVO may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to IV.
  - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 59%).
9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiaar-anticancer.org](mailto:journals@iiaar-anticancer.org).
11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.  
(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).

Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. J.M. BYUN, D. KIM, D.-Y. SHIN, I. KIM, Y. KOH, S.-S. YOON ( <i>Seoul, Republic of Korea</i> ) .....	611
Perioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience. D. SCHIZAS, N.A. THEOCHARI, C.A. THEOCHARI, D.G. KOKKINIDIS, V. DOMI, E. MPAILI, A.K. JONNALAGADDA, A. KAPELOUZOU, A. BAKOPOULOS, T. LIAKAKOS ( <i>Athens, Greece; Bronx, NY; Washington, DC, USA</i> ) .....	621
Endothelial Microparticles and Blood Coagulation Activation in Head and Neck Cancer Patients Undergoing Radiotherapy or Radiochemotherapy. E. SIERKO, M. SOBIERSKA, E. ZABROCKA, M. MYŚLIWIEC, J. KRUSZEWSKA, A. LIPSKA, P. RADZIWON, M.Z. WOJTUKIEWICZ ( <i>Bialystok, Poland; Stony Brook, NY, USA</i> ) .....	627
Clinicopathological Characteristics of Well-differentiated Papillary Mesothelioma of the Peritoneum: A Single-institutional Experience of 12 Cases. M. KIM, H.-S. KIM ( <i>Seoul, Republic of Korea</i> ) .....	633
Palonosetron on Days 1 and 5 Versus Granisetron Daily (Days 1-5) in Germ Cell Tumour Therapy. Y. SHIMURA, K. IZUMI, S. ITAI, H. IWAMOTO, H. YAEGASHI, Y. SUGA, T. SHIMADA, A. MIZOKAMI, Y. SAI ( <i>Kanazawa, Japan</i> ).....	643
Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer. D.W. BAEK, B.W. KANG, S.J. LEE, H.J. KIM, S.Y. PARK, J.S. PARK, G.S. CHOI, J.H. BAEK, J.G. KIM ( <i>Daegu, Republic of Korea</i> ) .....	649

Carbon Ion Radiotherapy in the Management of Unusual Liposarcomas: A Case Report. V. VITOLO, A. BARCELLINI, P. FOSSATI, M.R. FIORE, B. VISCHIONI, A. IANNALFI, A. FACOETTI, M. BONORA, S. RONCHI, E. D'IPPOLITO, R. PETRUCCI, G. VISELNER, L. PREDA, M. CIOCCA, F. VALVO, R. ORECCHIA ( <i>Pavia; Milan, Italy</i> ).....	529
Clinical and Radiological Mid-to-Long-term Outcomes Following Ankle Arthrolysis. F.-I. ROHLFING, U. WIEBKING, P.F. O'LOUGHLIN, C. KRETTEK, R. GAULKE ( <i>Hannover, Germany; Cork, Ireland</i> ).....	535
A Cross-sectional Survey of the Clinical Manifestations and Underlying Illness of Cough. T. OTOSHI, T. NAGANO, Y. FUNADA, K. TAKENAKA, H. NAKATA, H. OHNISHI, T. NISHIUMA, T. NAKAJIMA, T. KAGESHITA, T. TSUCHIYA, M. YAMAMOTO, K. KOBAYASHI, Y. NISHIMURA ( <i>Kobe; Takatsuki; Akashi, Japan</i> ).....	543
Primary Mediastinal HER2-positive Apocrine Carcinoma in Mature Teratoma Treated With Anti-HER2 Therapy and Chemoradiation. K. SUGIYAMA, A. IWAKOSHI, M. SATOH, K. SHIRAIISHI, K. NOZAWA, Y. KOGURE, C. KITAGAWA, S. MORITANI, E. KATOH, H. SAKA ( <i>Nagoya; Nagakute; Otsu, Japan</i> ).....	551
ACE Gene Variant Causing High Blood Pressure May Be Associated With Medication-related Jaw Osteonecrosis. C. YAPIJAKIS, V. PAPAKOSTA, S. VASSILIOU ( <i>Athens, Greece</i> ).....	559
Severe Encephalopathy, Lactic Acidosis and Hyperammonaemia With FOLFIRI Plus Aflibercept After Two-stage Hepatectomy: A Case Report. Y. HARA, Y. MIYAMOTO, Y. HIYOSHI, M. IWATSUKI, Y. BABA, N. YOSHIDA, H. BABA ( <i>Kumamoto, Japan</i> ).....	563
Infrared and Raman Spectroscopic Studies of Molecular Disorders in Skin Cancer. J. ANASTASSOPOULOU, M. KYRIAKIDOU, E. MALESIOU, M. RALLIS, T. THEOPHANIDES ( <i>Athens, Greece</i> ).....	567
The Association Between Sleep Disorders and the Risk of Colorectal Cancer in Patients: A Population-based Nested Case–Control Study. C.-L. LIN, T.-C. LIU, Y.-N. WANG, C.-H. CHUNG, W.-C. CHIEN ( <i>Taoyuan; Taipei, Taiwan, ROC; Oxford, UK</i> ).....	573
Endothelial Microparticles and Vascular Endothelial Growth Factor in Patients With Head and Neck Cancer Undergoing Radiotherapy or Radiochemotherapy. E. SIERKO, M. SOBIERSKA, E. ZABROCKA, J. KRUSZEWSKA, M. MYŚLIWIEC, A. LIPSKA, P. RADZIWON, M.Z. WOJTUKIEWICZ ( <i>Bialystok, Poland; Stony Brook, NY, USA</i> ).....	581
Postoperative Level of C-Reactive Protein Is a Prognosticator After Esophageal Cancer Surgery With Perioperative Steroid Therapy and Enhanced Recovery After Surgery Care. K. KANO, T. AOYAMA, Y. MAEZAWA, T. HAYASHI, T. YAMADA, H. TAMAGAWA, T. SATO, H. CHO, T. YOSHIKAWA, Y. RINO, M. MASUDA, T. OSHIMA, T. OGATA ( <i>Kanagawa, Japan</i> ).....	587
Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting <i>EGFR</i> Mutations in Matched Tumor Tissue, Cell Block, Pleural Effusion and Blood of Lung Cancer Patients With Malignant Pleural Effusion. S.H. JEON, H.W. KIM, B.N. KIM, N. KANG, C.D. YEO, C.K. PARK, Y.K. KIM, Y.H. LEE, T.-J. KIM, K.Y. LEE, S.H. LEE, J.Y. PARK, M.S. PARK, H.W. YIM, S.J. KIM ( <i>Seoul, Republic of Korea; Tampa, FL, USA</i> ).....	595
Radiation-induced Oral Mucositis in Brazilian Patients: Prevalence and Associated Factors. I.F. PEREIRA, R.T. FIRMINO, H.C. MEIRA, B.C. DO EGITO VASCONCELOS, V.R.A. DE SOUZA NORONHA, V.R. SANTOS ( <i>Camaragibe; Belo Horizonte, Brazil</i> ).....	605

Hypoxia of Rats Subjected to Carotid Artery Ligation Results in Impaired Neurogenesis and Reduced Number of Cortical Neurons. Y. CHUNG, H. CHO, G.H. JO, Y. JUN ( <i>Gwang-ju, Republic of Korea</i> ) ....	441
Comprehensive Analysis of Somatic Mutations in Colorectal Cancer With Peritoneal Metastasis. J.-H. LEE, B.K. AHN, S.S. BAIK, K.H. LEE ( <i>Gyeongju; Seoul, Republic of Korea</i> ).....	447
<i>Clinical Studies</i>	
Mid- to Long-term Outcomes After Split-thickness Skin Graft vs. Skin Extension by Multiple Incisions. J.N. KERN, F. WEIDEMANN, P.F. O'LOUGHLIN, C. KRETTEK, R. GAULKE ( <i>Hannover, Germany; Cork, Ireland</i> ) .....	453
Contribution of Serum Biomarkers to Prognostic Assessment in Patients With Oligometastatic Prostate Cancer. C. NIEDER, A. DALHAUG, A. PAWINSKI ( <i>Bodø; Tromsø, Norway</i> ) .....	465
Predictors of Postpartal Retained Products of Conception. F. THANGARAJAH, M. BRUNNER, C. PAHMEYER, J.C. RADOSA, C. EICHLER, S. LUDWIG, B. MORGENSTERN, P. MALLMANN ( <i>Cologne; Homburg, Germany</i> ) .....	469
Feasibility of Carbon Ion Radiotherapy in the Treatment of Gynecological Melanoma. A. BARCELLINI, V. VITOLO, A. FACOETTI, P. FOSSATI, L. PREDA, M.R. FIORE, B. VISCHIONI, A. IANNALFI, M. BONORA, S. RONCHI, E. D'IPPOLITO, R. PETRUCCI, G. VISELNER, M. CIOCCA, F. VALVO, R. ORECCHIA ( <i>Pavia; Milan, Italy</i> ).....	473
Gefitinib Plus Bevacizumab vs. Gefitinib Alone for <i>EGFR</i> Mutant Non-squamous Non-small Cell Lung Cancer. C. KITAGAWA, M. MORI, M. ICHIKI, N. SUKOH, A. KADA, A.M. SAITO, Y. ICHINOSE ( <i>Nagoya; Toyonaka; Fukuoka; Sapporo, Japan</i> ) .....	477
Breast Cancer in Lean Postmenopausal Women Might Have Specific Pathological Features. T. UOMORI, Y. HORIMOTO, A. ARAKAWA, K. IIJIMA, M. SAITO ( <i>Tokyo, Japan</i> ) .....	483
Cadaveric Study on Retrograde Calcaneotibial Fixation of Unstable Ankle Fractures. E.M. LOSCHAN, P. O'LOUGHLIN, C. KRETTEK, R. GAULKE ( <i>Hannover, Germany; Cork, Ireland</i> ) .....	489
Skin Extension by Multiple Incisions (SEMI). R. GAULKE ( <i>Hannover, Germany</i> ).....	495
Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients. M. SOHDA, H. SAITO, K. KURIYAMA, T. YOSHIDA, Y. KUMAKURA, H. HONJYO, K. HARA, D. OZAWA, S. SUZUKI, N. TANAKA, M. SAKAI, T. MIYAZAKI, M. FUKUCHI, H. KUWANO ( <i>Maebashi, Japan</i> ) .....	501
Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases. Y. AKANO, K. KURIBAYASHI, N. FUNAGUCHI, Y. KODA, E. FUJIMOTO, K. MIKAMI, T. MINAMI, R. TAKAHASHI, T. YOKOI, T. KIJIMA ( <i>Hyogo; Gifu, Japan</i> ) .....	507
Successful Implantation and Live Birth Following Autologous Platelet-rich Plasma Treatment for a Patient With Recurrent Implantation Failure and Chronic Endometritis. K. SFAKIANOUDIS, M. SIMOPOULOU, N. NITSOS, L. LAZAROS, A. RAPANI, A. PANTOU, M. KOUTSILIERIS, Y. NIKAS, K. PANTOS ( <i>Athens, Greece</i> ) .....	515
The Impact of Low Muscle Mass in Patients Undergoing Emergency Surgery for Colonic Perforation – A Single-center Experience. H. IMAMURA, M. HARAGUCHI, S. MINAMI, Y. ISAGAWA, M. MORITA, M. HIRABARU, D. KAWAHARA, H. TOKAI, K. NODA, K. INOUE, S. EGUCHI ( <i>Nagasaki, Japan</i> ).....	523

Establishment of a Primary Culture System of Human Periodontal Ligament Cells that Differentiate into Cementum Protein 1-expressing Cementoblast-like Cells. H. KADOKURA, T. YAMAZAKI, Y. MASUDA, Y. KATO, A. HASEGAWA, H. SAKAGAMI, S. YOKOSE ( <i>Saitama, Japan</i> ).....	349
$\beta$ -Hydroxy- $\beta$ -methylbutyrate Suppresses NF- $\kappa$ B Activation and IL-6 Production in TE-1 Cancer Cells. S. MIYAKE, A. OGO, H. KUBOTA, F. TERAMOTO, T. HIRAI ( <i>Kurashiki, Japan</i> ) .....	353
The Effect of Haemostatic Dressing Prototypes for the Emergency Services in the Porcine Haemostatic System. Z. ADAMIAK, J. BORYS, W. KRYSKIEWICZ, A. POMANIOWSKI, M. JALYNSKI, P. HOLAK, M. BRZEZINSKI, P. JASTRZEBSKI, A. TOBOLSKA, J. GLODEK ( <i>Olsztyn; Bialystok; Gdansk, Poland</i> ) .....	359
Salivary Glycine Is a Significant Predictor for the Attenuation of Polyp and Tumor Microenvironment Formation by Fucoxanthin in AOM/DSS Mice. M. TERASAKI, S. MASAKA, C. FUKADA, M. HOUZAKI, T. ENDO, T. TANAKA, H. MAEDA, K. MIYASHITA, M. MUTOH ( <i>Hokkaido; Gifu; Aomori; Tokyo, Japan</i> ) .....	365
Anticancer Effects of Baicalein in FRO Thyroid Cancer Cells Through the Up-regulation of ERK/p38 MAPK and Akt Pathway. S.E. HAN, C.H. PARK, I.S. NAM-GOONG, Y.I. KIM, E.S. KIM ( <i>Ulsan, Republic of Korea</i> ).....	375
Ursolic Acid Induces Apoptotic Cell Death Through AIF and Endo G Release Through a Mitochondria-dependent Pathway in NCI-H292 Human Lung Cancer Cells <i>In Vitro</i> . C.-J. CHEN, Y.-L. SHIH, M.-Y. YEH, N.-C. LIAO, H.-Y. CHUNG, K.-L. LIU, M.-H. LEE, P.-Y. CHOU, H.-Y. HOU, J.-S. CHOU, J.-G. CHUNG ( <i>Miaoli; Taipei; New Taipei; Changhua; Taichung, Taiwan, ROC</i> ) .....	383
The Pathogenic Effect of Cortactin Tyrosine Phosphorylation in Cutaneous Squamous Cell Carcinoma. L. ZHU, E. CHO, G. ZHAO, M.R. ROH, Z. ZHENG ( <i>Yanji, PR China; Seoul; Incheon, Republic of Korea</i> ) .....	393
Pentoxifylline Enhances the Apoptotic Effect of Carboplatin in Y79 Retinoblastoma Cells. C.C. CRUZ-GALVEZ, P.C. ORTIZ-LAZARENO, E.J. PEDRAZA-BRINDIS, M.M. VILLASENOR-GARCIA, E. REYES-URIBE, A. BRAVO-HERNANDEZ, R.A. SOLIS-MARTINEZ, M. CANCINO-MARENTES, C. RODRIGUEZ-PADILLA, A. BRAVO-CUELLAR, G. HERNANDEZ-FLORES ( <i>Guadalajara; Ocotlan; San Nicolas de los Garza; Tepatitlan de Morelos, Mexico</i> ).....	401
The Evaluation of Proteoglycan Levels and the Possible Role of ACAN Gene (c.6423T>C) Variant in Patients With Lumbar Disc Degeneration Disease. C.K. YALTIRIK, Ö. TIMIRCI-KAHRAMAN, S. GULEC-YILMAZ, S. OZDOGAN, B. ATALAY, T. ISBIR ( <i>Istanbul, Turkey</i> ) .....	413
Osteogenic Evaluation of Goose-beak Bones According to Processing Temperature. J.M. KIM, S.H. CHOI ( <i>Seoul; Cheongju, Republic of Korea</i> ) .....	419
Fusigen Reduces Intracellular Reactive Oxygen Species and Nitric Oxide Levels. V. KITTYANANT, P. LOTRAKUL, C. KANCHANABANCA, P. PADUNGROS, H. PUNNAPAYAK, S. PRASONGSUK, P. CHANVORACHOTE ( <i>Bangkok, Thailand; Surabaya, Indonesia</i> ) .....	425
Altered Resistin Concentrations in Mid-trimester Amniotic Fluid of Fetuses With Trisomies 18 and 13: A Window onto the Pathophysiology of Trisomies 18 and 13. N. VRACHNIS, E. DALAKLI, D. ZYGOURIS, N. VLACHADIS, N. SALAKOS, D. BOTSIS, S. KALANTARIDOU, N. DRAKOULIS, G. MASTORAKOS, G. CREATSAS, E. DELIGEOROGLOU, Z. ILIODROMITI ( <i>Athens, Greece</i> ) .....	433